An N6-methyladenosine-Related Classification Predicts Prognosis and Response to Immunotherapy in Prostate cancer

Yaru Zhu,Zhen Ren,Jianliang Shen,Xi Chen,Tong Zi,Xin Qin,Yan Zhao,Haopeng Li,Qiang Wu,Gang Wu,Licheng Wang
DOI: https://doi.org/10.21203/rs.3.rs-2661691/v1
2023-01-01
Abstract:Abstract The m6A modification is a methylation of the adenosine N6 position, is a kind of reversible post-transcriptional modification of RNA. Moreover, this process has been shown to be associated with multiple tumor progression. Prostate cancer is the second most common cancer in men after lung cancer, and is closely related to m6A. However, previous studies were often limited to a few m6A related genes, and failed to fully understand the relationship between prostate cancer and m6A.Therefore, we used the CIBERSORT and ESTIMATE algorithms to define three m6A clusters based on the expression of m6A-related genes in 1099 PC patients. Subsequently, we identified three different m6A gene clusters based on the overlap of differentially expressed genes (DEGs) within the m6A clusters. In addition, by principal component analysis (PCA) was performed to calculate the m6A scores. The results showed that patients with high m6A scores had longer survival time and those with low scores had shorter survival time. Furthermore, the m6A score was negatively correlated with the tumor mutation burden (TMB) value of PC. Patients with higher m6A scores showed clinical benefit and advantage of immunotherapy, indicating that the m6A score is an accurate and valid predictor to assess the effect of immunotherapy. Overall, our study presents a new method for reference that can provide guidance for current immunotherapy and predict patient prognosis to help physicians make judgments about patient disease and treatment modalities, and can guide current research on immunotherapy strategies for PC.
What problem does this paper attempt to address?